388 related articles for article (PubMed ID: 26525103)
1. T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.
Stromnes IM; Schmitt TM; Hulbert A; Brockenbrough JS; Nguyen H; Cuevas C; Dotson AM; Tan X; Hotes JL; Greenberg PD; Hingorani SR
Cancer Cell; 2015 Nov; 28(5):638-652. PubMed ID: 26525103
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.
Jindal V; Arora E; Masab M; Gupta S
Med Oncol; 2018 May; 35(6):84. PubMed ID: 29728788
[TBL] [Abstract][Full Text] [Related]
3. Engineered T cells for pancreatic cancer treatment.
Katari UL; Keirnan JM; Worth AC; Hodges SE; Leen AM; Fisher WE; Vera JF
HPB (Oxford); 2011 Sep; 13(9):643-50. PubMed ID: 21843265
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Watanabe K; Luo Y; Da T; Guedan S; Ruella M; Scholler J; Keith B; Young RM; Engels B; Sorsa S; Siurala M; Havunen R; Tähtinen S; Hemminki A; June CH
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618658
[TBL] [Abstract][Full Text] [Related]
5. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma.
Stromnes IM; Burrack AL; Hulbert A; Bonson P; Black C; Brockenbrough JS; Raynor JF; Spartz EJ; Pierce RH; Greenberg PD; Hingorani SR
Cancer Immunol Res; 2019 Jun; 7(6):977-989. PubMed ID: 31028033
[TBL] [Abstract][Full Text] [Related]
6. Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells.
Alrifai D; Sarker D; Maher J
Immunopharmacol Immunotoxicol; 2016; 38(1):50-60. PubMed ID: 26473647
[TBL] [Abstract][Full Text] [Related]
7. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response.
Ekkirala CR; Cappello P; Accolla RS; Giovarelli M; Romero I; Garrido C; Garcia-Lora AM; Novelli F
Pancreas; 2014 Oct; 43(7):1066-72. PubMed ID: 24987872
[TBL] [Abstract][Full Text] [Related]
8. T cell optimization for the treatment of pancreatic cancer.
Liu F; Saif MW
Expert Opin Biol Ther; 2017 Dec; 17(12):1493-1501. PubMed ID: 28835191
[TBL] [Abstract][Full Text] [Related]
9. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.
Raj D; Yang MH; Rodgers D; Hampton EN; Begum J; Mustafa A; Lorizio D; Garces I; Propper D; Kench JG; Kocher HM; Young TS; Aicher A; Heeschen C
Gut; 2019 Jun; 68(6):1052-1064. PubMed ID: 30121627
[TBL] [Abstract][Full Text] [Related]
10. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.
Beatty GL; O'Hara MH; Lacey SF; Torigian DA; Nazimuddin F; Chen F; Kulikovskaya IM; Soulen MC; McGarvey M; Nelson AM; Gladney WL; Levine BL; Melenhorst JJ; Plesa G; June CH
Gastroenterology; 2018 Jul; 155(1):29-32. PubMed ID: 29567081
[TBL] [Abstract][Full Text] [Related]
11. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma.
Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L
Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230
[TBL] [Abstract][Full Text] [Related]
12. Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma.
Yazdanifar M; Zhou R; Grover P; Williams C; Bose M; Moore LJ; Wu ST; Maher J; Dreau D; Mukherjee AP
Cells; 2019 Sep; 8(9):. PubMed ID: 31514488
[TBL] [Abstract][Full Text] [Related]
13. Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.
Hundeyin M; Kurz E; Mishra A; Rossi JAK; Liudahl SM; Leis KR; Mehrotra H; Kim M; Torres LE; Ogunsakin A; Link J; Sears RC; Sivagnanam S; Goecks J; Islam KMS; Dolgalev I; Savadkar S; Wang W; Aykut B; Leinwand J; Diskin B; Adam S; Israr M; Gelas M; Lish J; Chin K; Farooq MS; Wadowski B; Wu J; Shah S; Adeegbe DO; Pushalkar S; Vasudevaraja V; Saxena D; Wong KK; Coussens LM; Miller G
Cancer Discov; 2019 Sep; 9(9):1288-1305. PubMed ID: 31266770
[TBL] [Abstract][Full Text] [Related]
14. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.
Chao T; Furth EE; Vonderheide RH
Cancer Immunol Res; 2016 Nov; 4(11):968-982. PubMed ID: 27737879
[TBL] [Abstract][Full Text] [Related]
15. B cell-Derived IL35 Drives STAT3-Dependent CD8
Mirlekar B; Michaud D; Lee SJ; Kren NP; Harris C; Greene K; Goldman EC; Gupta GP; Fields RC; Hawkins WG; DeNardo DG; Rashid NU; Yeh JJ; McRee AJ; Vincent BG; Vignali DAA; Pylayeva-Gupta Y
Cancer Immunol Res; 2020 Mar; 8(3):292-308. PubMed ID: 32024640
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma.
Schmiechen ZC; Stromnes IM
Front Immunol; 2020; 11():613815. PubMed ID: 33584701
[TBL] [Abstract][Full Text] [Related]
17. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF
Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267
[TBL] [Abstract][Full Text] [Related]
18. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model.
Schmidt T; Ziske C; Märten A; Endres S; Tiemann K; Schmitz V; Gorschlüter M; Schneider C; Sauerbruch T; Schmidt-Wolf IG
Cancer Res; 2003 Dec; 63(24):8962-7. PubMed ID: 14695214
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo.
Nagaraj S; Ziske C; Strehl J; Messmer D; Sauerbruch T; Schmidt-Wolf IG
Int Immunol; 2006 Aug; 18(8):1279-83. PubMed ID: 16772371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
